GlassScriptPhysician profile
Betsy A George
NPI 1679644371
$6,965.09
in general payments reported to CMS, 2019-2025
33 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $260 · 2021: $724 · 2022: $1,022 · 2023: $1,510 · 2024: $1,325 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,169.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $849.64 | 2019-2025 | |
| Pfizer INC. | $820.87 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $744.57 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $697.28 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $550.04 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $547.89 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.84 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $369.04 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $308.76 | 2021-2025 | Verquvo |
| Medtronic, INC. | $300.82 | 2023-2025 | Symplicity G3, Corevalve Evolut R |
| Esperion Therapeutics, INC. | $141.78 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $135.97 | 2021-2023 | Rybelsus, Ozempic |
| Philips North America LLC | $133.64 | 2022-2025 | (Ck4) Mcot, Extended Holter, (Ck7) Extended Holter |
| Kiniksa Pharmaceuticals, LTD. | $102.87 | 2021-2023 | Arcalyst |
| Scpharmaceuticals INC. | $87.31 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $82.50 | 2023-2025 | Bodyguardian, Watchman Access System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.24 | 2022-2025 | Lifevest |
| Heartflow, INC. | $67.14 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.30 | 2021-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $61.06 | 2024 | Arcalyst |
| Recor Medical INC | $51.87 | 2024 | Paradise Renal Denervation System |
| Cvrx, INC. | $37.39 | 2022-2023 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $34.91 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $29.05 | 2023 | Optimizer |
| Convatec INC. | $28.30 | 2023 | |
| Ge Healthcare | $27.70 | 2023 | |
| Lantheus Medical Imaging, INC. | $21.34 | 2024 | |
| Spectrawave, INC | $18.27 | 2024 | Starlight Imaging Catheter, Hypervue Imaging System |
| Astellas Pharma US INC | $18.22 | 2020 | |
| Teleflex LLC | $16.20 | 2023 | Supercross |
| Regeneron Healthcare Solutions, INC. | $15.54 | 2019 | |
| Baxter Healthcare | $13.08 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Tactile Systems Technology INC | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.